Analyst Price Targets — DRUG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2026 10:57 am | Pat Trucchio | H.C. Wainwright | $145.00 | $81.02 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Bright Minds Biosciences Inc. (DRUG) |
| May 20, 2026 10:44 am | — | Piper Sandler | $220.00 | $74.54 | TheFly | Bright Minds price target raised to $220 from $190 at Piper Sandler |
| February 13, 2026 2:15 pm | — | Robert W. Baird | $126.00 | $78.71 | TheFly | Bright Minds price target lowered to $126 from $142 at Baird |
| January 7, 2026 12:56 pm | — | Robert W. Baird | $142.00 | $81.70 | TheFly | Bright Minds price target raised to $142 from $82 at Baird |
| January 7, 2026 11:42 am | — | BTIG | $147.00 | $93.21 | TheFly | Bright Minds price target raised to $147 from $72 at BTIG |
| May 7, 2025 8:45 am | Rudy Li | Chardan Capital | $80.00 | $29.02 | TheFly | Bright Minds initiated with a Buy at Chardan |
| January 10, 2025 11:09 am | Patrick Trucchio | H.C. Wainwright | $85.00 | $38.89 | TheFly | Bright Minds Biosciences initiated with a Buy at H.C. Wainwright |
Latest News for DRUG
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming…
Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DRUG.
U.S. House Trading
No House trades found for DRUG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.